Cerity Partners LLC Decreases Position in Sotera Health (NASDAQ:SHC)

Cerity Partners LLC reduced its stake in shares of Sotera Health (NASDAQ:SHC - Free Report) by 40.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,940 shares of the company's stock after selling 36,219 shares during the period. Cerity Partners LLC's holdings in Sotera Health were worth $750,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Sotera Health by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company's stock valued at $204,154,000 after acquiring an additional 173,341 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Sotera Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 2,780,445 shares of the company's stock valued at $38,048,000 after buying an additional 25,054 shares during the period. Bank of New York Mellon Corp increased its holdings in Sotera Health by 45.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company's stock valued at $22,308,000 after purchasing an additional 507,147 shares during the last quarter. Norges Bank purchased a new position in Sotera Health during the 4th quarter valued at about $12,764,000. Finally, Barclays PLC grew its position in Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company's stock valued at $7,909,000 after acquiring an additional 298,085 shares in the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SHC. Piper Sandler cut their price target on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Wednesday. Barclays decreased their price target on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.20.

Sotera Health Price Performance

NASDAQ SHC traded up $0.16 during mid-day trading on Thursday, hitting $11.03. The stock had a trading volume of 125,930 shares, compared to its average volume of 1,200,128. The company has a market cap of $3.13 billion, a price-to-earnings ratio of 44.06 and a beta of 1.88. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08. The company has a 50 day simple moving average of $11.65 and a 200 day simple moving average of $13.23.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.